Prescription Drug Search Results: Levora

Vorapaxar Meets End Point But Ups Bleeding Vorapaxar Meets End Point But Ups Bleeding
In its second phase 3 trial, Merck's novel antiplatelet agent reduced ischemic events but increased bleeding, including ICH. Results looked more promising in patients without a history of stroke. Heartwire (Source: Medscape Today Headlines)

5 innovative ways mental health care is more accessible
The mental health community is working to make treatment more accessible to Canadians through technology, art and changes in care. (Source: CTV Health)